Johnson Pharma

Who are the top shareholders of the Johnson Pharma?

The top shareholders of Johnson Pharma are primarily individual investors, holding 85.56% of the shares, with Jagkarta Agencies Private Limited as the largest public shareholder at 2.78%. There are no institutional holdings or pledged promoter holdings reported.

The top shareholders of Johnson Pharma primarily consist of individual investors, who hold a significant 85.56% of the shares. The highest public shareholder is Jagkarta Agencies Private Limited, with a holding of 2.78%. There are no institutional holdings or pledged promoter holdings reported, and no mutual funds or foreign institutional investors are involved.

how big is Johnson Pharma?

As of Jun 06, Johnson Pharmacare Ltd has a market capitalization of 49.50 Cr, with recent net sales of 0.00 Cr and a net profit of -0.58 Cr. Shareholder's funds are reported at 56.75 Cr and total assets at 59.83 Cr.

As of Jun 06, Johnson Pharmacare Ltd has a market capitalization of 49.50 Cr, categorizing it as a Micro Cap company.<BR><BR>As of Jun 06, the company's recent quarterly performance shows a sum of Net Sales for the latest 4 quarters at 0.00 Cr and a sum of Net Profit at -0.58 Cr. This data is based on Standalone financials.<BR><BR>As of Mar 24, the Balance Sheet Snapshot indicates Standalone data for the latest annual period, with Shareholder's Funds reported at 56.75 Cr and Total Assets at 59.83 Cr.

Who are in the management team of Johnson Pharma?

As of March 2022, the management team of Johnson Pharma includes Ramanlal Trivedi as the Whole Time Director and CFO, along with Independent Directors Pareshbhai Sengal and Manisha Maneklal Patel.

As of March 2022, the management team of Johnson Pharma includes Ramanlal Trivedi, who serves as the Whole Time Director and CFO. Additionally, the board features two Independent Directors: Pareshbhai Sengal and Manisha Maneklal Patel.

What does Johnson Pharma do?

Johnson Pharmacare Ltd, a micro-cap company in India, engages in the purchase and sale of goods and services. Founded in 1994 and renamed in 2021, it reported a net profit of -1 Cr for March 2025, with a market cap of Rs 49 Cr.

Overview: <BR>Johnson Pharmacare Ltd is engaged in the purchase and sale of goods and services in India, operating within the diversified commercial services industry and classified as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 1994 under the name 'Robinson Worldwide Trade Limited', changed its name to 'Sun & Shine Worldwide Limited' in September 2011, and was renamed to 'Johnson Pharmacare Limited' on August 23, 2021. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 49 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 30 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.03 <BR>Return on Equity: -0.72% <BR>Price to Book: 0.86<BR><BR>Contact Details: <BR>Address: Office No 302 Munisuvrat Navg, NTC B-68 Swastik Society CG Rd Ahmedabad Gujarat : 380009 <BR>Email: sunandshineworldwideltd@gmail.com <BR>Website: http://www.sunandshineworldwidetradelimited.quest

What is the bonus history of the Johnson Pharma?

Johnson Pharma announced a 1:10 bonus issue on April 7, 2022, with a record date of April 8, 2022, meaning shareholders received one additional share for every ten shares held.

Johnson Pharma has a recent bonus history that includes a 1:10 bonus issue announced on April 7, 2022. The record date for this bonus was April 8, 2022. This means that for every 10 shares held, shareholders received an additional share as part of the bonus issue. If you have any more questions about the company or its financials, feel free to ask!

Has Johnson Pharma declared dividend?

No Dividend History Available

Who are the peers of the Johnson Pharma?

Johnson Pharma's peers include International Ge, CMS Info Systems, NESCO, SIS, Nirlon, Rithwik Facility, Satchmo Holdings, Enbee Trade, and Innovative Ideal. Their management risk and growth vary, with Nirlon showing the highest 1-year return at 22.15% and Johnson Pharma at -11.76%.

Peers: The peers of Johnson Pharma are International Ge, CMS Info Systems, NESCO, SIS, Nirlon, Rithwik Facility, Satchmo Holdings, Enbee Trade, and Innovative Ideal.<BR><BR>Quality Snapshot: Excellent management risk is observed at International Ge and the rest have either Good, Average, or Below Average management risk. Growth is Average at Nirlon and Johnson Pharma, while Below Average growth is found at CMS Info Systems, NESCO, SIS, Rithwik Facility, and Innovative Ideal, with the rest having Excellent growth. Capital Structure is Excellent at International Ge and CMS Info Systems, Good at Johnson Pharma and SIS, while Below Average is noted at Nirlon and Innovative Ideal, and the rest have varying ratings.<BR><BR>Return Snapshot: Nirlon has the highest 1-year return at 22.15%, while Enbee Trade has the lowest at -41.99%. Johnson Pharma's 1-year return is -11.76%, which is higher than Enbee Trade's but lower than Nirlon's. Additionally, several peers, including NESCO, SIS, Satchmo Holdings, Enbee Trade, and Innovative Ideal, have negative six-month returns.

Is Johnson Pharma overvalued or undervalued?

As of May 27, 2024, Johnson Pharma is considered overvalued with a PE ratio of -48.95 and has seen a year-to-date decline of 21.05%, indicating a challenging market position compared to its peers.

As of 27 May 2024, Johnson Pharma's valuation grade has moved from very expensive to risky, indicating a significant shift in its market perception. The company is currently assessed as overvalued, with a PE ratio of -48.95, an EV to EBIT of -50.90, and an EV to Capital Employed of 0.87. These ratios suggest that the company's earnings and operational efficiency are under considerable strain, leading to negative valuations.<BR><BR>In comparison to its peers, Johnson Pharma's valuation metrics are starkly unfavorable. For instance, MMTC, categorized as risky, has a PE ratio of 119.39, while Optiemus Infra, deemed fair, boasts a PE of 82.35. The stark contrast in these ratios highlights Johnson Pharma's challenging position within the diversified commercial services sector. Furthermore, the company's recent stock performance shows a year-to-date decline of 21.05%, in contrast to the Sensex's 5.58% gain, reinforcing the notion that Johnson Pharma is struggling relative to broader market trends.

What is the technical trend for Johnson Pharma?

As of April 30, 2025, Johnson Pharma's technical trend has shifted to a moderate bearish stance, supported by bearish indicators across MACD, RSI, and Bollinger Bands on both weekly and monthly charts, despite a mildly bullish KST on the weekly.

As of 30 April 2025, the technical trend for Johnson Pharma has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart and a bearish RSI on the monthly chart. Both Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The daily moving averages confirm a bearish outlook. Although the KST shows mildly bullish on the weekly, it is mildly bearish on the monthly, indicating a lack of strong upward momentum. Overall, the bearish sentiment is reinforced by the Dow Theory, which shows a mildly bearish trend on the weekly and no trend on the monthly.

How has been the historical performance of Johnson Pharma?

Johnson Pharma has experienced significant declines in revenue and profitability, with net sales dropping from 3.26 Cr in March 2022 to 0.00 Cr by March 2025, resulting in increasing operating and net losses. Total assets and liabilities decreased, and cash flow turned negative, indicating a downward trend in financial stability.

Answer:<BR>The historical performance of Johnson Pharma shows significant fluctuations in revenue and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Johnson Pharma's net sales peaked at 3.26 Cr in March 2022 but have since dropped to 0.00 Cr in March 2025. Total operating income followed a similar trend, decreasing from 3.26 Cr in March 2022 to 0.00 Cr in March 2025. The company experienced an operating profit of 0.13 Cr in March 2022, but this turned negative, resulting in an operating loss of 0.41 Cr by March 2025. Profit before tax also saw a decline, moving from a profit of 0.13 Cr in March 2022 to a loss of 0.58 Cr in March 2025. The profit after tax mirrored this trend, with losses increasing from 0.10 Cr in March 2022 to 0.58 Cr in March 2025. Total assets decreased from 59.98 Cr in March 2022 to 57.93 Cr in March 2025, while total liabilities also fell from 59.98 Cr to 57.93 Cr in the same period. Cash flow from operating activities turned negative, with a cash outflow of 1.00 Cr in March 2025, contrasting with a positive cash flow of 4.00 Cr in March 2022. Overall, the financial data indicates a downward trajectory in both operational performance and financial stability for Johnson Pharma.

When is the next results date for Johnson Pharmacare Ltd?

The next results date for Johnson Pharmacare Ltd is 14 February 2026.

The next results date for Johnson Pharmacare Ltd is scheduled for 14 February 2026.

Should I buy, sell or hold Johnson Pharmacare Ltd?

Why is Johnson Pharmacare Ltd falling/rising?

As of 02-Jun, Johnson Pharmacare Ltd's stock price is at 0.55, unchanged from the previous session, and has underperformed its sector by 0.93%. The stock has shown significant declines over the past year and a notable decrease in investor participation, contributing to its stagnant price movement.

As of 02-Jun, Johnson Pharmacare Ltd's stock price is currently at 0.55, with no change from the previous trading session. The stock has underperformed its sector by 0.93% today, indicating a decline in performance relative to its peers. Over the past week, the stock has remained flat at +0.00%, while the benchmark Sensex has decreased by 1.79%. <BR><BR>In the longer term, the stock has shown a decline of 6.78% over the past month and 5.17% year-to-date, which is better than the Sensex's decline of 2.94% and 12.40%, respectively. However, the stock has significantly underperformed over the past year, with a drop of 38.89% compared to the Sensex's 8.26% decline. <BR><BR>Additionally, there is a notable decrease in investor participation, as evidenced by a 15.48% drop in delivery volume compared to the 5-day average. This suggests a lack of interest or confidence among investors, contributing to the stock's stagnant price movement. The stock is currently trading higher than its 5-day moving averages but lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a mixed trend in its short-term performance. <BR><BR>Overall, the combination of underperformance against the sector, declining investor participation, and significant losses over the past year are contributing factors to the stock's current stagnation and lack of upward momentum.

Which are the latest news on Johnson Pharma?